Bicycle Therapeutics (NASDAQ:BCYC) Rating Reiterated by Morgan Stanley

Morgan Stanley restated their equal weight rating on shares of Bicycle Therapeutics (NASDAQ:BCYC – Free Report) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $42.00 target price on the stock. A number of other equities analysts have also commented on the stock. HC Wainwright reissued a buy rating and […]

Related Keywords

,Kevin Lee ,Bicycle Therapeutics Company Profile ,Needham Company ,Ef Hutton Acquisition Co ,Morgan Stanley ,Securities Exchange Commission ,Tower Research Capital ,Exchange Traded Concepts ,Nasdaq ,Bicycle Therapeutics ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Research Capital ,Traded Concepts ,Membrane Type ,Bicycle Therapeutics Daily ,Nasdaq Bcyc ,Bcyc ,Medical ,Reiterated Rating ,